LONGi achieves new milestone as first solar brand to exceed 20GW in module shipments in 2020

PR Newswire

XI’AN, China, Dec. 3, 2020 /PRNewswire/ — LONGi has set a new record for being the first solar brand to exceed 20GW in shipments of PV modules in 2020.

Since its foundation in 2000, LONGi has always been market oriented and customer focused, continuously developing high-efficiency, high-reliability and high-quality solar products and PV solutions in order to provide customers with value-added services.

Customer Focus

LONGi has established global unified systems for customer complaint handling, service standards, quality monitoring and management processes. Customers can therefore be confident that any problems will be resolved in a timely manner.

Thanks to high-quality wafers, high-efficiency PERC cells and strict requirements regarding module materials and processes, LONGi modules consistently demonstrate excellent performance in third-party reliability tests, energy yield evaluations and client applications. LONGi works with B&V, TÜV SÜD, TÜV Rheinland, RETC and other institutions to build global pilot projects to evaluate the energy yield performance of its modules.

In the PV Tech Bankability rankings, LONGi remains the only AAA-Rated module supplier for the fourth consecutive quarter in 2020. This continues to be driven by the company’s strong track record of being a global 20GW module supplier.

Commitment to Innovation

With a strong commitment to R&D and innovation, LONGi has a strong track record of being a reliable supplier with high-efficiency modules (Hi-MO 1 to Hi-MO 5). Because of savings in LCOE and BOS costs, coupled with their high energy yield, LONGi modules have earned wide recognition around the world.

LONGi’s all new Hi-MO 5 bifacial module, based on the newly built M10 cell, was launched globally this year for delivery to investors in utility-scale PV plants. The company’s new range of products reflects its commitment to delivering consistent value to global clients through innovation.


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/longi-achieves-new-milestone-as-first-solar-brand-to-exceed-20gw-in-module-shipments-in-2020-301186277.html


Seagate Announces Pricing of $1 Billion of Senior Unsecured Notes

Seagate Announces Pricing of $1 Billion of Senior Unsecured Notes

Seagate HDD Cayman (the “Company”), a subsidiary of Seagate Technology plc (NASDAQ: STX) (“Seagate”), announced that it priced its earlier announced offering of $500 million aggregate principal amount of senior notes due 2029 (the “2029 Notes”) and $500 million aggregate principal amount of senior notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Notes”). The 2029 Notes were priced at 100% of the aggregate principal amount and will bear interest at a rate of 3.125% per annum. The 2031 Notes were priced at 100% of the aggregate principal amount and will bear interest at a rate of 3.375% per annum. The Notes will be guaranteed by Seagate.

The Notes are being sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and in offshore transactions under Regulation S under the Securities Act. The sale of the Notes is expected to close on December 8, 2020, subject to customary closing conditions.

Seagate intends to use the net proceeds from the offering of the Notes for repurchases of Seagate’s ordinary shares and for general corporate purposes, which may include repayment of other outstanding indebtedness, capital expenditures and other investments in the business.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Notes to be offered have not been and will not be registered under the Securities Act, or applicable state securities laws, and may not be offered or sold in the United States absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

About Seagate

Seagate crafts the datasphere, helping to maximize humanity’s potential by innovating world-class, precision-engineered data management solutions with a focus on sustainable partnerships.

© 2020 Seagate Technology LLC. All rights reserved. Seagate, Seagate Technology and the Spiral logo are registered trademarks of Seagate Technology LLC in the United States and/or other countries.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical fact. Forward-looking statements include, among other things,statements about the terms and conditions of, and completion of, the offering of the Notes and the use of proceeds therefrom, each as described above. The Company cannot assure that the offering will be consummated, nor can it guarantee the size or terms of the offering. Forward-looking statements generally can be identified by words such as “expects,” “intends, “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “should,” “may,” “will,” “will continue”, “can”, “could” or the negative of these words, variations of these words and comparable terminology. These forward-looking statements are conditioned upon and also involve a number of known and unknown risks, uncertainties, and other factors that could cause actual results, performance or events to differ materially from those anticipated by these forward-looking statements. Such risks, uncertainties and other factors may be beyond the Company’s control and may pose a risk to the Company’s operating and financial condition. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on, and which speak only as of, the date hereof. The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, unless required by applicable law.

Investor Relations Contact:

Shanye Hudson, (510) 661-1714


KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Hardware Data Management Consumer Electronics Technology Software



ComEd Helps Eight More Engineering Students Pursue STEM Careers

ComEd Helps Eight More Engineering Students Pursue STEM Careers

Students from Illinois Tech and the University of Illinois Chicago are latest group of ComEd Scholars to receive financial support, mentoring and internship opportunities

To help local students attain their STEM education goals, while developing a workforce that is as diverse as the communities it serves, ComEd today announced it will again provide scholarships to northern Illinois students pursuing engineering degrees that fill the tuition gap not covered by financial aid. Eight new students make up the ComEd Scholars program’s newest class of recipients that attend the Illinois Institute of Technology (Illinois Tech) and the University of Illinois Chicago (UIC).

“ComEd lifts up the communities it serves and the first step in that process is helping young people further their education and pursue their dreams,” said Michelle Blaise, ComEd’s senior vice president of technical services and an Illinois Tech mechanical engineering alumna. “This year in particular, students and their families face economic challenges. By supporting these students now, we hope they will gain the education necessary to develop the innovations that help local communities succeed in the future.”

Now in its second year, the ComEd Scholars program provides scholarships that fill education-related expenses not covered by financial aid, allowing students to pursue STEM degrees locally for the rest of their undergraduate careers. Additionally, ComEd Scholars are guaranteed an opportunity to interview for internships at ComEd and its parent company, Exelon, and are invited to participate in a mentorship program with ComEd engineers. ComEd has previously provided scholarships to four students through this program.

To qualify for the ComEd Scholars program, students are first recommended by their respective schools. Each school’s financial aid office then partners with academic advisors to identify high-performing students facing financial burdens to continue their education. Prospective recipients must then submit a personal statement, financial-aid application and school transcripts.

The 2020 ComEd Scholars are:

  • Daniel Arechiga – a second-year student from Lockport, Ill.,pursuing a degree in electrical engineering at Illinois Tech.
  • Neil Young – a second-year student from Freeport, Ill.,pursuing a degree in mechanical engineering at Illinois Tech.
  • Lake Crowell – a third-year student from Chicago’s Near West Side neighborhood, pursuing a degree in industrial engineering atUIC.
  • Victoria Dorris – a third-year student from Chicago’s Humboldt Park neighborhood, pursuing a degree in industrial engineering at UIC.
  • Sultan Muhammad – a second-year student from Dolton, Ill., pursuing a degree in mechanical engineering at UIC.
  • Anahi Soto – a second-year student from Maywood, Ill., pursuing a degree in electrical engineering at UIC.
  • Lauren-Charlise Walls – a second-year student from Chicago’s Avalon Park neighborhood,pursuing a degree in electrical engineering at UIC.
  • Caleb Williams – a second-year student from Chicago’s Auburn Gresham neighborhood, pursuing a degree in electrical engineering at UIC.

“ComEd’s unwavering leadership and support is a testament to their commitment to investing in the talented young minds that will shape the future of STEM,” said UIC CHANCE Director Kendal Parker.

“ComEd’s philanthropy provides funds that completely fill tuition gaps not covered by financial aid, plus a pathway to mentorship and internship opportunities,” said Ernie Iseminger, vice president for Advancement at Illinois Tech. “Our ComEd scholars are pursuing degrees in Engineering, have mentored for Illinois Tech’s Exelon Summer Institute for incoming students, and participate in student groups such as the Illinois Tech chapter of the Society of Automotive Engineers.”

“We thank ComEd for once again making an investment in our students at Illinois Tech,” said Illinois Tech President Alan W. Cramb. “Providing our students with access to a world-class STEM education is central to Illinois Tech’s mission and these scholarships will allow them to focus on their studies and post-graduate careers on building the technological innovations of tomorrow.”

ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 100 energy company with approximately 10 million electricity and natural gas customers – the largest number of customers in the U.S. ComEd powers the lives of more than 4 million customers across northern Illinois, or 70 percent of the state’s population. For more information visit ComEd.com and connect with the company on Facebook, Twitter, Instagram and YouTube.

Illinois Institute of Technology, also known as Illinois Tech, is a private, technology-focused research university. Illinois Tech is the only university of its kind in Chicago, and its Chicago location offers students access to the world-class resources of a great global metropolis. It offers undergraduate and graduate degrees in engineering, computing, architecture, business, design, science and human sciences, and law. One of 23 institutions that comprise the Association of Independent Technological Universities, Illinois Tech provides an exceptional education centered on active learning, and its graduates lead the state and much of the nation in economic prosperity. Illinois Tech uniquely prepares students to succeed in professions that require technological sophistication, an innovative mindset, and an entrepreneurial spirit. Visit iit.edu.

Located in the heart of one of the world’s great cities, the University of Illinois Chicago is the city’s largest university and only public research institution. Its 16 academic colleges serve more than 33,000 undergraduate, graduate and professional students. UIC is recognized as one of the most ethnically rich and culturally diverse campuses in the nation, a leader in providing access to underrepresented students. With one of the largest colleges of medicine in the nation, and colleges of dentistry, pharmacy, public health, nursing, social work, and applied health sciences, UIC is the state’s principal educator of health professionals and a major healthcare provider to underserved communities. UIC students become professionals in fields ranging from law and business to engineering to education, liberal arts and sciences, urban planning, and social work, as well as architecture, design and the arts. UIC is an integral part of the educational, technological, and cultural fabric of one of the world’s greatest cities. Visit uic.edu.

ComEd Media Relations


KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Other Energy Utilities Philanthropy Oil/Gas Nuclear Coal Alternative Energy Energy Other Education University Education Other Philanthropy



Sigilon Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the pricing of its upsized initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share. All of the shares are being offered by Sigilon. In addition, Sigilon has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Sigilon’s common stock is expected to begin trading on the Nasdaq Global Market on December 4, 2020 under the symbol “SGTX.”

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sigilon, are expected to be $126.0 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2020, subject to the satisfaction of customary closing conditions.

Morgan Stanley, Jefferies, Barclays and Canaccord Genuity are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on December 3, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department or via email: prospectus@morganstanley.com; and from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing and size of the proposed initial public offering of our common stock. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the proposed initial public offering. There can be no assurance that we will be able to complete our initial public offering on the anticipated terms, or at all. Applicable risks also include those identified under the heading “Risk Factors” in the Company’s registration statement on Form S-1. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.


Media Contact

Amy Bonanno
Solebury Trout

ECMOHO ALERT: Bragar Eagel & Squire, P.C. is Investigating ECMOHO Limited on Behalf of ECMOHO Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ECMOHO Limited (NASDAQ: MOHO) on behalf of ECMOHO stockholders. Our investigation concerns whether ECMOHO has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On or around November 8, 2019, ECMOHO completed its initial public offering (“IPO”), issuing 4,375,000 American Depositary Shares (“ADSs”) priced at $10.00 per ADS.  On November 30, 2020, post-market, ECMOHO reported its financial results for the third quarter of 2020.  Among other results, ECMOHO reported GAAP EPS of -$0.03 on revenue of $71.45 million, representing a decline of approximately 4.6% compared to revenue for the same period in the prior year. 

Since the IPO, ECMOHO’s ADSs have closed as low as $1.30 per ADS, representing a decline of 87% from the offering price.

If you purchased or otherwise acquired ECMOHO shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

& Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648

Successful 1031 DST Investment Completed for Mother-Daughter Duo

LOS ANGELES, Dec. 03, 2020 (GLOBE NEWSWIRE) — Kay Properties today announced the completion of a 1031 DST investment for a mother-daughter duo. The pair sold a vacation rental property they owned for many years. They were eager to exit the highly management-intensive environment of operating vacation rentals and enter into a more passive, diversified investment structure such as the DST. They utilized the Kay Properties 1031 DST marketplace at www.kpi1031.com to invest in a prepackaged multifamily DST portfolio.

Kay Properties
elps with 1031 DST

The Delaware Statutory Trust exchange investment was completed by Kay Properties and Investments team members Chay Lapin, Senior Vice President, and Matt McFarland, Vice President.

Chay Lapin, Senior Vice President, stated, “We are grateful for the opportunity to help another family complete a 1031 DST exchange. They now are involved in a more passive investment environment to better suit their lifestyle. Our clients approached us with a very high level of sophistication of buying and selling their own real estate over many years. When considering all their options, they decided that the Delaware Statutory Trust structure was best suited for their needs.”

Lapin continued, “Through on and off correspondence for over a year and a half, the clients were able to complete their own due diligence on DSTs. They spent time with us learning about how DSTs could potentially help them all while utilizing the DST investment marketplace at www.kpi1031.com/marketplace.”

Teamwork at Kay Properties
ompletes 1031 DST in timely manner for clients

Matt McFarland, Vice President at Kay Properties, stated, “This particular client was able to exchange out of a management-intensive vacation rental. The 1031 up leg was a multifamily DST offering with multiple properties totaling over 900 units. Needless to say, this $100M+ multifamily portfolio is an investment that would have been out of reach to many investors if it weren’t for the DST structure.”

About Kay Properties and 


Kay Properties is a national Delaware Statutory Trust (DST) investment firm. The www.kpi1031.com platform provides access to the marketplace of DSTs from over 25 different sponsor companies, custom DSTs only available to Kay clients, independent advice on DST sponsor companies, full due diligence and vetting on each DST (typically 20-40 DSTs) and a DST secondary market. 

Kay Properties team members collectively have over 115 years of real estate experience, are licensed in all 50 states, and have participated in over $15 billion of DST 1031 investments.

*Diversification does not guarantee profits or protect against losses. *This case study may not be representative of the experience of other clients. Past performance does not guarantee or indicate the likelihood of future results. Please speak with your attorney and CPA before considering an investment. 

Risks and Disclosures

This material does not constitute an offer to sell nor a solicitation of an offer to buy any security. Such offers can be made only by the confidential Private Placement Memorandum (the “Memorandum”). Please read the entire Memorandum paying special attention to the risk section prior to investing. 1031, 1033 and 721 exchanges are complex tax codes therefore you should consult your tax or legal professional for details regarding your situation. There are material risks associated with investing in real estate securities including illiquidity, vacancies, general market conditions and competition, lack of operating history, interest rate risks, general risks of owning/operating commercial and multifamily properties, financing risks, potential adverse tax consequences, general economic risks, development risks and long hold periods. There is a risk of loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, potential returns and potential appreciation are not guaranteed. Securities offered through Growth Capital Securities. Member FINRA/SIPC. Kay Properties and Investments, LLC and Growth Capital Securities are separate entities.

Media contacts for more information:

Cary Brazeman, 310-205-3590, cary@crelix.com
Victoria Ozols, 310-205-3590, victoria@crelix.com

RM LAW Announces Class Action Lawsuit Against JOYY Inc.

PR Newswire

BERWYN, Pa., Dec. 3, 2020 /PRNewswire/ — RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased JOYY Inc. (“JOYY” or the “Company”) (NASDAQ:YY) securities during the period from April 28, 2016 through November 18, 2020 inclusive (the “Class Period”).

JOYY shareholders may, no later than January 19, 2021 move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of JOYY and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) the majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company’s acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you are a member of the class, you may, no later than January 19, 2021 request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as “lead plaintiff.”  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain RM LAW, P.C. or other counsel of your choice, to serve as your counsel in this action.

For more information regarding this, please contact RM LAW, P.C.  (Richard A. Maniskas, Esquire) toll-free at (844) 291-9299 or by email at rm@maniskas.com or click here.   For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website by clicking here

 RM LAW, P.C. is a national shareholder litigation firm.  RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.



Richard A. Maniskas, Esquire

1055 Westlakes Dr., Ste. 300

Berwyn, PA 19312




Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rm-law-announces-class-action-lawsuit-against-joyy-inc-301186268.html


iQIYI Scores Big Wins at 2020 Golden Rooster Awards

‘My Himalayas’ and ‘Flaming Cloud’ Win best low-budget feature, most promising director and other accolades at the prestigious film event

PR Newswire

BEIJING, Dec. 3, 2020 /PRNewswire/ — iQIYI Inc. (NASDAQ: IQ) (“iQIYI” or the “Company”), an innovative market-leading online entertainment service in China, is pleased to announce that two of its films, My Himalayas and Flaming Cloud, won multiple awards at the prestigious 33rd China Film Golden Rooster Awards.

My Himalayas scooped the award for Best Low-Budget Feature while Flaming Cloud won the awards for Most Promising Director, Superior Project in Selected Category and Most Recommended Project by Investors, which beat over 1,000 films submitted in its category. In addition, Wang Rui won Best Director for Chaogtu with Sarula, which will be aired on iQIYI platform.

iQIYI has always partnered with filmmakers in areas such as production, copyright collaboration and online distribution to explore new ways of storytelling and business modes, supporting them by providing distribution channels for films of all genres to reach viewers worldwide.

As a co-producer and distributer of low-to-medium budget films, iQIYI keeps an eye on outstanding filmmakers who have inspiring stories to tell.

A number of works jointly produced by iQIYI, including The Summer Is Gone, Mirrors and Feathers and The Moment of Pluto, have attracted attention at international film festivals. Balloon, which is currently in theaters, and the forthcoming Tough Out have been widely acclaimed for their creative narrative structures and touching performances.

With regards to art films, iQIYI has always been a strong supporter and advocate. Apart from Chaogtu with Sarula, the exclusive copyrights of which were acquired by iQIYI, many other quality Chinese art films such as What’s In The Darkness, The Summer is Gone, Kaili Blues, Love Education, Spring Tide and Dwelling in the Fuchun Mountains, as well as award-winning overseas titles La La Land, Happy as Lazzaro and Bohemian Rhapsody have all been picked up by iQIYI for online streaming. The combination of indie and mainstream titles complement each other and helps diversify iQIYI’s content offering, providing a richer selection of films for iQIYI’s users. 

iQIYI also owns the exclusive copyright of three Golden Rooster Awards winners, namely, Liberation, Ne Zha and Better Days, showcasing the Company’s strong purchasing power.

Going forward, iQIYI will continue to work with professionals in the film industry in a wide range of areas spanning production, copyright collaboration and online distribution.

While it did not win any awards, iQIYI’s art film Spring Tide was nominated for Best Feature Film and Best Director. The film, distributed through the Company’s premium video-on-demand (PVOD) channel, received wide attention and garnered an exceptional reputation immediately following its online release. The nominations once again confirmed that high-quality films and inspiring stories can transcend modes of distribution and screen sizes to generate the same emotional reactions and enjoyment. 

Launched in 1981, the Golden Rooster Awards is widely considered as one of the most prestigious awards for Chinese-language films.

This year, a total of 155 films were shortlisted and 19 winners announced during the four-day film festival, which concluded on November 28 at the Strait Grand Theater in Xiamen, east China’sFujian Province.

About iQIYI, Inc.

iQIYI, Inc. is an innovative market-leading online entertainment service in China. Its corporate DNA combines creative talent with technology, fostering an environment for continuous innovation and the production of blockbuster content. iQIYI’s platform features highly popular original content, as well as a comprehensive library of other professionally-produced content, partner-generated content and user generated content. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a massive user base with tremendous user engagement, and has developed a diversified monetization model including membership services, online advertising services, content distribution, live broadcasting, online games, IP licensing, online literature and e-commerce.

Cision View original content:http://www.prnewswire.com/news-releases/iqiyi-scores-big-wins-at-2020-golden-rooster-awards-301186267.html


dynaCERT Announces Voting Results of Annual Meeting

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) (“dynaCERT” or the “Company”) is pleased to announce the results of the annual and special meeting of its shareholders, which was completed today (the “Meeting”). Out of concern for the safety of dynaCERT‘s employees, shareholders and other stakeholders in light of the COVID‐19 pandemic, and in accordance with current public health rules and guidelines concerning in‐person gatherings, the Meeting was held virtually via the Lumi annual meeting platform pursuant to suggestions by the Company’s registrar and transfer agent and scrutineers, TSX Trust Company. A total of 106,024,254 common shares of the Company (each, a “Common Share”), representing 28.85% of the total Common Shares outstanding, were represented in person or by proxy at the Meeting. dynaCERT’s shareholders voted in favor of all items of business put forward at the Meeting, being the election of all nominated directors, the re‐appointment of BDO Canada LLP as the auditors of the Company, the approval of the Company’s amended and restated stock option plan and the approval of the Company’s restricted share unit plan.

The votes in respect of each of these items were held via ballot, the results of which were as follows:

Description of Matter Voted Upon
Result of

Votes by Ballot

Votes For

# (%)


# (%)



# (%)
1. Ordinary resolution fixing the number of directors at seven (7) Passed 105,247,595 (99.27%) 776,659 (0.73%)  
2. Ordinary resolution approving the election of the following nominees as directors of the Corporation

  • James Payne
  • Robert Maier
  • Jean-Pierre Colin
  • Wayne Hoffman
  • Richard Lu
  • Elliot Strashin
  • Amir Farahi


102,419,255 (96.60%)
102,645,195 (96.81%)
98,376,987 (92.79%)
99,725,196 (94.06%)
100,918,168 (95.18%)
99,641,269 (93.98%)
99,252,189 (93.61%)


3,604,999 (3.40%)
3,379,059 (3.19%)
7,647,267 (7.21%)
6,299,058 (5.94%)
5,106,086 (4.82%)
6,382,985 (6.02%)
6,772,065 (6.39%)

3. Ordinary resolution approving the appointment of BDO Canada LLP as auditors of the Corporation Passed 105,447,732 (99.46%)   576,522 (0.54%)
4. Ordinary resolution approving the amended and restated Stock Option Plan of the Corporation Passed 70,155,113 (66.17%) 35,869,141 (33.83%)  
5. Ordinary resolution approving the Restricted Share Unit Plan of the Corporation Passed 96,826,462 (91.32%) 9,197,792 (8.68%)  






 Inc. manufactures and distributes Carbon Emission Reduction Technology for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, resulting in lower carbon emissions and greater fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment, marine vessels and railroad locomotives. Website: www.dynaCERT.com.


Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may”
Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance
of achievements.
the same, in whole or in part, as those set out in the forward-looking

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that
forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability
success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at


. Readers are cautioned that this list of risk factors should not be construed as

The forward-looking information contained in this news release is expressly qualified by this cautionary
to conform such information to actual results or to changes in our expectations except as otherwise required
on forward-looking

tock Exchange
nor its Regulation Services Provider (as that term is defined in the policies of the T
tock Exchange
) accepts responsibility for the adequacy or accuracy of the release.

On Behalf of the Board

Murray James Payne, CEO

For more information, please contact:

Jim Payne, CEO & President
dynaCERT Inc.
#101 – 501 Alliance Avenue
Toronto, Ontario M6N 2J1
+1 (416) 766-9691 x 2

Investor Relations
dynaCERT Inc.
Nancy Massicotte
+1 (416) 766-9691 x 1


BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

—Significant and sustained reduction in HAE attacks—



, once-daily

prophylactic option


HAE pat


ents to reduce

burden of therapy1 

ORLADEYO approved for adult and pediatric patients

12 years and older

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved oral, once-daily ORLADEYO™ (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

“ORLADEYO offers people with HAE and their physicians the first orally administered non-steroidal option for preventing HAE attacks and represents an important and welcome step in making more treatment options available to physicians and patients,” said Anthony J. Castaldo, president and chief executive officer of the US Hereditary Angioedema Association (HAEA). 

In the pivotal Phase 3 APeX-2 trial, ORLADEYO significantly reduced attacks at 24 weeks, and this reduction was sustained through 48 weeks. HAE patients who completed 48 weeks of treatment (150 mg) saw reductions in their HAE attack rates, from a mean of 2.9 attacks per month at baseline to a mean of 1.0 attacks per month after 48 weeks of therapy. In the long-term open label APeX-S trial, patients completing 48 weeks of therapy (150 mg) had a mean attack rate of 0.8 attacks per month.

ORLADEYO was safe and well tolerated in both trials. The most frequently reported adverse reactions in patients receiving ORLADEYO compared with placebo were gastrointestinal reactions. These reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.

“Patients and physicians acknowledge that HAE treatments can add a burden to patients’ lives.  As an oral, once-daily option, ORLADEYO can provide significant attack reduction and lessen the burden associated with injections and infusions,” said Marc Riedl, M.D., professor of medicine and clinical director, U.S. Hereditary Angioedema Association Center at the University of California, San Diego, and an investigator in the APeX-2 trial.

“With this new treatment option, physicians and patients can continue to have collaborative discussions to choose the treatment that meets each patient’s needs, life circumstances and preferences,” Riedl added.

HAE patients note a significant treatment burden associated with existing prophylactic therapy. In addition to reducing HAE attack rate, data from APeX-2 show that patients reported meaningful improvements in both quality of life and overall patient-reported satisfaction, and significant reductions in their monthly use of standard of care on-demand medicine, while taking oral, once-daily ORLADEYO (150 mg).2,3

“The FDA approval of ORLADEYO fulfills a promise BioCryst made to HAE patients that we were committed to helping them achieve the dream of an oral, once-daily medicine to prevent and reduce the burden of their attacks,” said Jon Stonehouse, president and chief executive officer of BioCryst.

“Thank you to the HAE patients who participated in our clinical trials, to the investigators around the world who conducted these trials, to the HAEA for their patient advocacy and to our employees who never forgot that patients were waiting. We will stay focused on enabling access and providing personalized support to HAE patients and physicians,” Stonehouse added.

Commitment to Patient Access

BioCryst is committed to supporting HAE patients taking ORLADEYO through a new program designed to streamline access to therapy. Through EMPOWER Patient Services, each HAE patient and their healthcare provider will have a single point of contact for access to ORLADEYO. A dedicated care coordinator will support access for each patient with comprehensive financial support tools and reimbursement support.

EMPOWER Patients Services is administered by Optime Care Inc., the exclusive specialty pharmacy provider for ORLADEYO. Physicians can begin writing prescriptions for ORLADEYO immediately, with direct to patient shipments from Optime Care expected to begin by the end of December 2020.

Additional information is available at www.ORLADEYO.com and 1-866-5-EMPOWER (1-866-536-7693).



ORLADEYO™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.  One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information


ORLADEYO™ (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use

The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.


An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or



Please see full

Prescribing I


About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company’s website at www.biocryst.com.

Forward-Looking Statements 

This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for ORLADEYO.  These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, including to support the continued commercialization of ORLADEYO, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, including ORLADEYO, may impose a clinical hold with respect to such product candidates, or may withhold or withdraw market approval for such product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management’s expected ranges.  Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s forward-looking statements.



John Bluth
+1 919 859 7910

Catherine Collier Kyroulis
+1 917 886 5586

Radojicic, C, et al. Patient Perspectives on the Treatment Burden of Injectable Medication Administration for Hereditary Angioedema. Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 160, Nov (2020)

2 Johnston, D.T., et al. Berotralstat Improves Patient-Reported Quality of Life Through 48 Weeks in the Phase 3 APeX-2 Trial; Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 154, Nov (2020) 

3 Jacobs, J, et al. Berotralstat Positively Impacts Patient-Reported Satisfaction: Results from the Phase 3 APeX-2 trial; Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 158, Nov (2020)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf57a925-5da4-4c72-8a93-02e9c4308123